NPW1 Stock Chart & Stats
€14.30
€0.08(0.68%)
At close: 4:00 PM EST
€14.30
€0.08(0.68%)
Day’s Range― - ―
52-Week Range€12.50 - €16.57
Previous CloseN/A
Volume0.00
Average Volume (3M)192.00
Market Cap
€11.21B
Enterprise Value€12.80K
Total Cash (Recent Filing)€557.20M
Total Debt (Recent Filing)€3.33B
Price to Earnings (P/E)20.5
Beta0.54
Next Earnings
Aug 04, 2026EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.74
Shares Outstanding840,515,800
10 Day Avg. Volume0
30 Day Avg. Volume192
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.73
Price to Sales (P/S)2.30
P/FCF Ratio16.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€16.52Price Target Upside15.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)0.01
Revenue Forecast (FY)€77.04M
Bulls Say, Bears Say
Bulls Say
Improving Cash GenerationMaterial FCF improvement over 2024–2025 demonstrates enhanced cash generation capacity. Strong free cash flow supports reinvestment in R&D and new product launches, funds dividends and buybacks, and provides balance-sheet flexibility to absorb one-time items or opportunistic M&A without materially weakening solvency.
Innovation-led Product GrowthHigh share of growth from recent launches and a 2026 product cadence point to a durable pipeline and continuing adoption. New capital-equipment placements (e.g., CORI) and consumable-rich procedures increase recurring attach rates, supporting structural revenue growth and differentiation versus peers over the medium term.
Margin Expansion And Operating LeverageSustained margin expansion reflects operating leverage, product mix improvement, and achieved cost savings. Higher margins and planned efficiency savings increase structural profitability and ROIC potential, giving management room to invest in growth while preserving cash returns and debt capacity over the next several years.
Bears Say
China VBP Policy HeadwindVolume-based procurement (VBP) is a structural, policy-driven margin pressure that can compress pricing and profitability in China. Even though China is a small share of sales, ongoing VBP impacts create persistent pricing risk in a strategically important market and can limit revenue upside from that region.
Reimbursement Changes For Skin SubstitutesDurable reimbursement shifts reduce demand and unit economics for skin-substitute products in physician office and mobile channels. Given recurring nature of wound-care revenue, sustained reimbursement pressure materially erodes long-term revenue and profit visibility for the Advanced Wound Management franchise.
Inventory Write-down And Portfolio RationalizationA sizeable inventory write-down and aggressive SKU pruning signal execution costs and near-term earnings volatility while rationalizing the portfolio. Transition-related write-offs and operational changes can temporarily depress margins and require careful execution to realize intended efficiency and longer-term margin improvements.
Smith & Nephew News
NPW1 FAQ
What was Smith & Nephew plc’s price range in the past 12 months?
Smith & Nephew plc lowest stock price was €12.50 and its highest was €16.57 in the past 12 months.
What is Smith & Nephew plc’s market cap?
Smith & Nephew plc’s market cap is €11.21B.
When is Smith & Nephew plc’s upcoming earnings report date?
Smith & Nephew plc’s upcoming earnings report date is Aug 04, 2026 which is in 8 days.
How were Smith & Nephew plc’s earnings last quarter?
Smith & Nephew plc released its earnings results on Mar 02, 2026. The company reported €0.517 earnings per share for the quarter, beating the consensus estimate of €0.506 by €0.011.
Is Smith & Nephew plc overvalued?
According to Wall Street analysts Smith & Nephew plc’s price is currently Undervalued.
Does Smith & Nephew plc pay dividends?
Smith & Nephew plc does not currently pay dividends.
What is Smith & Nephew plc’s EPS estimate?
Smith & Nephew plc’s EPS estimate is 0.41.
How many shares outstanding does Smith & Nephew plc have?
Smith & Nephew plc has 840,515,800 shares outstanding.
What happened to Smith & Nephew plc’s price movement after its last earnings report?
Smith & Nephew plc reported an EPS of €0.517 in its last earnings report, beating expectations of €0.506. Following the earnings report the stock price went down -3.762%.
Which hedge fund is a major shareholder of Smith & Nephew plc?
Currently, no hedge funds are holding shares in DE:NPW1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Smith & Nephew Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€16.52 (15.50% Upside)
€16.52 (15.50% Upside)
Insider Transactions
Sold Shares
Worth €63.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.13%
12-Months-Change
Fundamentals
Return on Equity
2.50%
Trailing 12-Months
Asset Growth
-5.96%
Trailing 12-Months
Company Description
Smith & Nephew plc
Smith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for joint reconstruction. This segment also provides trauma and extremities products, including internal and external fixation devices crucial for stabilizing severe fractures and correcting deformities. In the sports medicine field, the company furnishes surgeons with comprehensive joint repair solutions. These encompass specialized instruments, advanced technologies, and implants necessary for minimally invasive joint surgeries, addressing soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, its arthroscopic enabling technologies support surgical visualization and intervention inside joints, comprising fluid management equipment, high-definition cameras, digital image capture systems, scopes, light sources, and monitors. It also supplies radiofrequency, electromechanical, and mechanical tissue resection devices, along with hand instruments for removing damaged tissue, and provides ear, nose, and throat (ENT) solutions. Furthermore, Smith & Nephew delivers sophisticated advanced wound management solutions. This category features products for the treatment and prevention of acute and chronic wounds, including leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Its offerings extend to advanced wound bioactives, incorporating biologics and other active technologies for debridement, dermal repair, and regeneration, as well as regenerative medicine products like skin, bone graft, and articular cartilage substitutes. The advanced wound devices portfolio includes traditional and single-use negative pressure wound therapy systems, alongside hydrosurgery devices. Primarily serving healthcare providers, Smith & Nephew plc was founded in 1856 and maintains its corporate headquarters in Watford, United Kingdom.
NPW1 Stock 12 Month Forecast
Average Price Target
€16.52
▲(15.50% Upside)
Technical Analysis
Advanced Medical Solutions
―
ConvaTec
―
Hikma Pharmaceuticals
―
PureTech Health
―
Spire Healthcare
―